Navigation Links
Why do people 'play the longshot' and buy insurance? It's in our genes

Jerusalem, January 11, 2010 Why do some people like to take risks by playing "longshot" payoffs while, on the other hand, taking the opposite tack by buying insurance to reduce risks? A team of economists and molecular geneticists from the Hebrew University of Jerusalem and two Asian universities say the answer can be found in our genetic makeup.

The team set out to tackle the long-standing question in economic theory as to why people tend to be risk-preferring when facing longshot risks involving significant gains, such as betting on race horses, and on the other hand are risk averse when facing significant losses -- buying home or car insurance, for instance.

Many economists have struggled with this paradox, says Richard Ebstein, the Sylvia Scheinfeld Professor of Human Genetics at the Hebrew University of Jerusalem, who has probed this subject along with economists Prof. Soo Hong Chew of the National University of Singapore (NUS) and Dr. Songfa Zhong of NUS and the Hong Kong University of Science and Technology.

Ebstein notes the psychological explanation suggested by former Hebrew University psychology Professors Daniel Kahneman (a Nobel Prize laureate) and Amos Tversky, as embodied in their widely accepted prospect theory, to explain why people play the lottery and at the same time purchase insurance. Although prospect theory offers a psychological explanation for this facet of economic behavior, the underlying neurobiological and neurogenetic mechanisms have remained obscure until now, said Ebstein.

In an article just published online on PLoS ONE, Ebstein and his colleagues combined the tools of experimental economics and molecular genetics to examine the role of a well-characterized gene, monoamine oxidase A (MAOA), in predicting whether subjects are more likely to buy the lottery or insurance (or both) under well-controlled laboratory conditions.

In the experiment, 350 Han Chinese subjects were recruited in Beijing and participated in two simple choice tasks, representing proclivities to purchase lottery tickets and insurance, using real monetary incentives.

For example, the subjects were given options to keep a very small cash return upfront, with no risk, or of gambling bigger amounts that they were given upfront but with a minimal chance of actually winning and keeping the money in a lottery drawing. In the second task, concerning insurance, subjects were asked whether or not they would insure a certain but insignificant loss or would take out insurance on a larger amount with a real but low risk of actual loss.

They found that subjects with a high-activity variation of the MAOA gene are characterized by a preference for the longshot lottery and also less insurance purchasing than subjects with the low-activity genetic version. This is the first result to link attitude towards longshot risks to a specific gene. It complements other, recent findings on the neurobiological basis of economic risk taking.

As the world financial system slowly emerges from the near economic meltdown, it is worth considering, says Ebstein, that inborn biases, coded by common genetic variants, may be a major factor in fueling people's actions regarding longshot options --- with concomitant effects on financial markets.


Contact: Jerry Barach
The Hebrew University of Jerusalem

Related biology news :

1. How people work ... and the fingerprint mystery
2. Toxicants detected in Asian monkey hair may warn of environmental threats to people and wildlife
3. Moderate weight loss in obese people improves heart function
4. Why cant some people give up cocaine?
5. Indiana U. at APHA: Studies about health education for people with ID, stability balls at work
6. Experimental treatments restore partial vision to blind people
7. Cell study explains why younger people more at risk of vCJD
8. Fish fend off invading germs with an initial response similar to the one found in people
9. Beta-blockers and stroke -- new insights into their use for older people
10. NIH-funded researchers sequence exomes of 12 people
11. $2 million grant aids study of lung cancer in people who never smoked
Post Your Comments:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: